nach oben

World Journal of Urology

Erschienen in:

01.09.2006 | Topic Paper

What patients take without telling you: holistic approach for BPH

verfasst von: Jillian L. Capodice, Aaron E. Katz

Erschienen in: World Journal of Urology | Ausgabe 4/2006

Einloggen, um Zugang zu erhalten

Abstract

The use of botanicals and supplements have markedly increased in men that are seeking increased protection against the potential onset and symptomatic relief of lower urinary tract symptoms that are commonly experienced with benign prostatic hyperplasia (BPH). While this implies a positive trend and considers that men are taking a more active role in health and prevention, dialog between the patient and the clinician is often deficient. This may be due to a number of factors including both the patients’ inability to report about the use of certain agents and the clinicians’ inability to ask. Moreover, the sense that natural agents may lack side effects coupled with ineffective communication between the doctor and patient could result in potential adverse interactions. We have performed a comprehensive search of articles published from 1990 to 2005 using the Medline databases in order examine clinical data on the most commonly researched herbs for BPH. We provide a brief update on the state of the research.

Beckman TJ, Mynderse LA (2005) Evaluation and medical management of benign prostatic hyperplasia. Mayo Clin Proc 80(10):1356–1362PubMedCrossRef

Kaplan SA (2005) Benign prostatic hyperplasia. J Urol 174(6):2281–2283CrossRef

Lowe FC (2004) Role of the newer alpha, adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 26(11):1701–1713PubMedCrossRef

Brown GA, Sussman DO (2004) A current review of medical therapy for benign prostatic hyperplasia. J Am Osteopath Assoc 104(2 Suppl 2):S11–S16PubMed

Gunther S, Patterson RE, Kristal AR, Stratton KL, White E (2004) Demographic and health-related correlates of herbal and specialty supplement use. J Am Diet Assoc 104(1):27–34PubMedCrossRef

Eng J, Ramsum D, Verhoef M, Guns E, Davison J, Gallagher R (2003) A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer. Integr Cancer Ther 2(3):212–216PubMedCrossRef

Klein EA (2006) Chemoprevention of prostate cancer. Annu Rev Med 57:49–63PubMedCrossRef

Dvorkin L, Song KY (2002) Herbs for benign prostatic hyperplasia. Ann Pharmacother 36(9):1443–1452PubMedCrossRef

Shoskes DA (2002) Phytotherapy and other alternative forms of care for the patient with prostatitis. Curr Urol Rep 3(4):330–334PubMedCrossRef

10.

Shukla S, Gupta S (2005) Dietary agents in the chemoprevention of prostate cancer. Nutr Cancer 53(1):18–32PubMedCrossRef

11.

Greenberg JA, Newmann SJ, Howell AB (2005) Consumption of sweetened dried cranberries versus unsweetened raisins for inhibition of uropathogenic Escherichia coli adhesion in human urine: a pilot study. J Altern Complement Med 11(5):875–878PubMedCrossRef

12.

Awad AB, Gan Y, Fink CS (2000) Effect of beta-sitosterol, a plant sterol, on growth, protein phosphatase 2A, and phospholipase D in LNCaP cells. Nutr Cancer 36(1):74–78PubMedCrossRef

13.

Cabeza M, Bratoeff E, Heuze I, Ramirez E, Sanchez M, Flores E (2003) Effect of beta-sitosterol as inhibitor of 5 alpha-reductase in hamster prostate. Proc West Pharmacol Soc 46:153–155PubMed

14.

Awad AB, Fink CS, Williams H, Kim U (2001) In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells. Eur J Cancer Prev 10(6):507–513PubMedCrossRef

15.

Berges RR, Windeler J, Trampisch HJ, Senge T (1995) Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet 345(8964):1529–1532PubMedCrossRef

16.

Klippel KF, Hiltl DM, Schipp B (1997) A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. Br J Urol 80(3):427–432PubMed

17.

Berges RR, Kassen A, Senge T (2000) Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up. BJU Int 85(7):842–846PubMedCrossRef

18.

Wilt TJ, MacDonald R, Ishani A (1999) beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int 83(9):976–983PubMedCrossRef

19.

Wilt T, Ishani A, MacDonald R, Stark G, Mulrow C, Lau J (2000) Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev (2):CD001043

20.

Medical Economics (ed) (1998) Physician’s desk reference (PDR) for herbal medicines. Thomson Healthcare, Montvale

21.

Yablonsky F, Nicolas V, Riffaud JP, Bellamy F (1997) Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts. J Urol 157(6):2381–2387PubMedCrossRef

22.

Chatelain C, Autet W, Brackman F (1999) Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. Urology 54(3):473–478PubMedCrossRef

23.

Breza J, Dzurny O, Borowka A, Hanus T, Petrik R, Blane G, Chadha-Boreham H (1998) Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe. Curr Med Res Opin 14(3):127–139PubMedCrossRef

24.

Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G (2002) Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev (1):CD001044

25.

Anderson ML (2005) A preliminary investigation of the enzymatic inhibition of 5alpha-reduction and growth of prostatic carcinoma cell line LNCap-FGC by natural astaxanthin and Saw Palmetto lipid extract in vitro. J Herb Pharmacother 5(1):17–26PubMedCrossRef

26.

Navarrete R, Escribano-Burgos M, Farre AL, Garcia-Cardoso J, Manzarbeitia F, Carrasco C (2005) Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. J Urol 173(2):507–510CrossRef

27.

Habib FK, Ross M, Ho CK, Lyons V, Chapman K (2005) Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer 114(2):190–194PubMedCrossRef

28.

Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, Lopez Farre A (2003) BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 44(5):549–555PubMedCrossRef

29.

Debruyne F, Boyle P, Calais Da Silva F, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP, Schulman CC (2004) Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. Eur Urol 45(6):773–779 disucssion 779–780

30.

Zlotta AR, Teillac P, Raynaud JP, Schulman CC (2005) Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), tamsulosin or finasteride. Eur Urol 48(2):269–276. Epub 2005

31.

Buck AC (2004) Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 172(5 Pt 1):1792–1799PubMedCrossRef

32.

McPartland JM, Pruitt PL (2000) Benign prostatic hyperplasia treated with saw palmetto: a literature search and an experimental case study. J Am Osteopath Assoc 100(2):89–96PubMed

33.

Wilt T, Ishani A, Mac Donald R (2002) Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev (3):CD001423

34.

Konrad L, Muller HH, Lenz C, Laubinger H, Aumuller G, Lichius JJ (2000) Antiproliferative effect on human prostate cancer cells by a stinging nettle root (Urtica dioica) extract. Planta Med 66(1):44–47PubMedCrossRef

35.

Sokeland J (2000) Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. BJU Int 86(4):439–442PubMedCrossRef

36.

Lopatkin N, Sivkov A, Walther C, Schlafke S, Medvedev A, Avdeichuk J, Golubev G, Melnik K, Elenberger N, Engelmann U (2005) Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms–a placebo-controlled, double-blind, multicenter trial. World J Urol 23(2):139–146. Epub 2005

37.

Carbajal D, Molina V, Mas R, Arruzazabala ML (2005) Therapeutic effect of d-004, a lipid extract from Roystonea regia fruits, on prostate hyperplasia induced in rats. Drugs Exp Clin Res 31(5–6):193–197PubMed

38.

Fujita R, Liu J, Shimizu K, Konishi F, Noda K, Kumamoto S, Ueda C, Tajiri H, Kaneko S, Suimi Y, Kondo R (2005) Anti-androgenic activities of Ganoderma lucidum. J Ethnopharmacol 102(1):107–112PubMedCrossRef

39.

Shibata Y, Kashiwagi B, Arai S, Fukabori Y, Suzuki K (2005) Administration of extract of mushroom Phellinus linteus induces prostate enlargement with increase in stromal component in experimentally developed rat model of benign prostatic hyperplasia. Urology 66(2):455–460PubMedCrossRef

40.

Mannel M (2004) Drug interactions with St John’s wort: mechanisms and clinical implications. Drug Saf 27(11):773–797PubMedCrossRef

41.

Singh YN (2005) Potential for interaction of kava and St. John’s wort with drugs. J Ethnopharmacol 100(1–2):108–113PubMedCrossRef

42.

Bressler R (2005) Herb-drug interactions. Interactions between saw palmetto and prescription medications. Geriatrics 60(11):32–34PubMed

43.

Miller LG (1998) Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 158(20):2200–2211PubMedCrossRef

Titel: What patients take without telling you: holistic approach for BPH
verfasst von: Jillian L. Capodice
Aaron E. Katz
Publikationsdatum: 01.09.2006
Verlag: Springer-Verlag
Erschienen in: World Journal of Urology / Ausgabe 4/2006
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-006-0093-z

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2006

Protective effects of taurine on protamine sulfate induced bladder damage

The evolution of photoselective vaporization prostatectomy (PVP): advancing the surgical treatment of benign prostatic hyperplasia

New approaches in the modulation of bladder smooth muscle cells on viable detrusor constructs

Laser treatment of symptomatic benign prostatic hyperplasia